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doi:10.1016/j.asjsur.2012.04.008Summary Choledochoduodenal fistula (CDF) complicated by peptic diseases or following
surgical or endoscopic approaches of the common bile duct is not uncommon. However, it
usually occurs without significant symptoms and can be well controlled with conservative
treatment in normal immunized patients. Here we report a case involving a 58-year-old male
patient with diabetic nephropathy, who received a choledocholithotomy for choledocholithia-
sis in November 2007 and renal transplantation in March 2008. The patient had recurring cho-
langitis during the 5 months following his renal transplantation. Cholangiography and liver
biopsy revealed sclerosing cholangitis. The patient underwent liver transplantation (LT) in
May 2009 because radiological and endoscopic procedures failed to control his jaundice. A
proximal CDF was found during the LT procedures. We considered that the patient’s advanced
secondary sclerosing cholangitis was induced by this fistula. At the 16 months’ follow-up, the
patient was surviving well and the graft remained intact. To our knowledge, this is the first
report of a renal transplantation recipient receiving LT because of uncontrolled cholangitis
caused by a CDF.
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50 W.-T. Chang et al.1. Introduction revealed rapid progressive dilatation of both extra- andSecondary sclerosing cholangitis (SSC), which is morpho-
logically and clinically similar to primary sclerosing chol-
angitis (PSC), usually originates from known pathological
processes, including choledochoduodenal fistula (CDF).1,2
Clinically, CDF is fairly common, and in patients in large
endoscopic retrograde cholangiopancreatography studies,
it has been reported to have an incidence ranging from
2.53% to5.3%.3,4 However, surgery for this complication,
especially liver transplantation (LT), is rarely necessary.1,2
Herewe report a case involving a uremic patient requiring
LT as a result of advanced SSC 19 months after a chol-
edocholithotomy and 10 months after renal transplantation.
During the LT, we found a CDF. To our knowledge, this
represents the first report of a renal transplantation recip-
ient requiring LT due to advanced SSC caused by a CDF.2. Case report
A 58-year-old male uremic patient received open chole-
cystectomy and choledocholithotomy for gall bladder
stones and choledocholithiasis in November 2007. The
T-tube was removed January 2008. The cholangiography
showed no biliary-enteric fistula (Fig. 1). The patient also
received living donor renal transplantation in March 2008
for diabetic nephropathy. The allograft was donated by
his wife and this graft was implanted in the left iliac fossa.
The maintenance immunosuppressive agents consisted of
a triple-drug regimen included tacrolimus, mycophenolate
sodium, and prednisolone. This patient did not suffer
from any clinically evident rejection episode and the
serum levels of blood sugar were acceptable after renal
transplantation.
Five months after renal transplantation, he started
having recurring episodes of intractable suppurative chol-
angitis. Magnetic resonance cholangiography in March 2009Figure 1 The cholangiography showed normal configuration
of the biliary tract. There was no residual choledocholithiasis,
no leakage of contrast, and no biliary-enteric fistula found.intrahepatic ducts and multifocal stricture and beading
throughout the bile ducts (Fig. 2). During cholangiography,
we found a proximal CDF (see Fig. 2, arrow), not previously
shown by endoscopic or radiological images. Computed
tomography (CT) showed normal perfusion of the extra- and
intrahepatic artery (Fig. 3).
Before liver transplantation, the patient’s liver enzymes
were:total bilirubin 12.43 mg/dL (0.1e1.6), aspartate
aminotransferase 76 IU/L (1e40), alanine aminotransferase
91 IU/L (1e40), and alkaline phosphatase 565 IU/L (30e115),
gamma glutamyl transpeptide 472 IU/L (8e35). Serological
tests for viral hepatitis B or C, antimitochondria antibody,
antinuclear antibody, and human immunodeficiency virus
were all negative. Neither cryptosporidium nor cytome-
galovirus was found in the bile or blood samples of this
patient. Colonoscopy showed no inflammatory bowel
disease. Liver and bile duct biopsy findings were compatible
with sclerosing cholangitis and without evidence of chol-
angiocarcinoma. LT was indicated because biliary cirrhosis
and hepatic failure were unresponsive to conservative
treatment, including percutaneous transhepatic biliary
drainage and endoscopic sphincterostomy (Figs. 4 and 5).
The patient received deceased donor LT in May 2009.
Intraoperatively, he was confirmed to have diffuse scle-
rosing cholangiopathy and a proximal type CDF, 1 X 0.7 X
0.2 cm, over the middle third common bile duct. Patho-
logical analysis of the native explanted liver found peri-
ductal fibrosis and ductular proliferation, plus centrilobular
cholestasis and necrosis. The CDF showed inflammatory
granulation tissue. This fistula was thought to have caused
the sclerosing cholangitis. The patient’s bile duct was
reconstructed with Roux-en-Y hepaticojejunostomy and, 16
months later, he is surviving well and the liver graft hasFigure 2 Multifocal stricture and beading throughout the
extra- and intrahepatic ducts was found by magnetic reso-
nance cholangiography in March 2009. The arrow shows the
proximal choledochoduodenal fistula.
Figure 3 The normal distribution of the extra- and intra-
hepatic artery and the patency of the portal vein were shown
by computed tomography. The renal graft was implanted in the
left iliac fossa.
Figure 5 The cholangiography of endoscopic sphincter-
ostomy (December 2008) showed progressive dilation of both
the intra- and extrahepatic biliary tract. There was no chol-
edochoduodenal fistula detected during the period of
treatments.
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leakage or stenosis of the anastomatosis, have been found.
3. Discussion
Compared with PSC, the natural history and prognosis of
SSC maybe more favorable if recognition is prompt andFigure 4 The cholangiography of initial cholangitis
(September 2008) showed there was dilated intrahepatic
biliary tract and no choledochoduodenal fistula visible when
percutaneous transhepatic biliary drainage was undergone.appropriate therapy timely.1,2 Conservative treatment
often fails in patients with advanced SSC, generally
because of ischemic changes in the biliary tract of patients
receiving surgical trauma or patients who are critically ill.2
Gossard et al5 reported that patients with advanced SSC
who do not undergo LT may have significantly lower survival
rates than patients with PSC.
In this case, the hepatic artery was intact (Fig. 3). Thus,
instead of diffuse ischemia, his sclerosing cholangitis was
probably caused by repeated cholangitis induced by prox-
imal CDF. Because cholangiopathy was diffuse and liver
parenchyma had irreversible sclerosing change, it would
not be appropriate to perform a simple fistula closure or
bypass.
Experience of using LT to treat SSC is limited. In
Gossard’s report,5 29% (9/31) of the patients with advanced
SSC needed LT, and four of those nine died, including one
who was waiting to receive the procedure. Mohsine,6
however, reported that five SSC patients survived well
after LT and all patients had no recurrence of cholangitis
after a median follow-up of 39 months.
Compression of the duodenal bulb by T-tube may have
contributed to the formation of the CDF in this patient. Its
small caliber made it difficult to recognize during previous
endoscopic and radiological procedures (Figs. 4 and 5).
Thus, no operation was performed to salvage the liver
before LT.
Tacrolimus and cyclosporine have cholestatic and lith-
ogeniceffects.7,8 Abdo et al9 reported the recovery of
a renal transplant patient suffering from reversible SSC
caused by cryptosporidiosis infection following a reduction
in tacrolimus dosage. Therefore, these calcineurin inhibi-
tors perhaps exacerbate the injury caused by toxin-
52 W.-T. Chang et al.producing bacteria, viruses, or other opportunistic patho-
gens to the biliary epithelium during the recurring episodes
of cholangitis.8,9 The dosage of tacrolimus prescribed for
this patient was adjusted to maintain serum trough levels
of 5e10 ng/mL for the first postoperative month and
5e7 ng/mL thereafter. These levels were lower than the
usually recommended protocol. Furthermore, SSC is not
more frequently encountered in LT patients who receive
a hepaticojejunostomy or choledochoduodenostomy and
take calcinerin inhibitors.10 Thus, the relationship between
calcineurin inhibitors and SSC in this case needs further
investigation.
In conclusion, the severe sequel of SSC due to CDF
should not be neglected in such immunocompromised
patients, as recipients of renal transplantations. LT can be
used to treat these patients with advanced SSC.References
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